Our patients with anti‐CNTN1 nodopathy had significantly more frequent sensory ataxia and a greater incidence of poor response to IVIg, which was consistent with earlier reports [4, 6, 16, 21]. The gene discussed is CNTN1; the disease is sensory ataxia.